Assertio Holdings, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark L. Reisenauer
- Full Time Employees
- 58
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 100 South Saunders Road Lake Forest IL United States of America 60045
- IPO Date
- Dec 3, 1997
- CIK
- 0001808665
- Website
- assertiotx.com
- Similar Companies
- Business
- Assertio Holdings, Inc. (ASRT) is a commercial pharmaceutical company focused on commercializing differentiated branded prescription products across neurology, pain and inflammation, oncology, and hospital sectors; its core offerings include ROLVEDON (eflapegrastim-xnst) injection for reducing febrile neutropenia in patients receiving myelosuppressive chemotherapy, INDOCIN (indomethacin) suppositories and oral suspension as nonsteroidal anti-inflammatory drugs (NSAIDs) for moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute gouty arthritis, and painful shoulder conditions, Sympazan (clobazam) oral film as a benzodiazepine for adjunctive seizure treatment in Lennox-Gastaut syndrome patients aged two years and older, Otrexup (methotrexate) injection for subcutaneous use in autoimmune conditions, SPRIX (ketorolac tromethamine) nasal spray for moderate to severe pain, CAMBIA (diclofenac potassium) oral solution for acute migraine treatment including pain, photophobia, phonophobia, and nausea, and Zipsor (diclofenac potassium) liquid-filled capsules for mild to moderate acute pain. The company employs an omni-channel commercial model integrating digital marketing, non-personal promotion, and specialized field sales teams, particularly for oncology products like ROLVEDON, while pursuing growth via acquisitions, licensing, and mergers across therapeutic areas. Founded in 1995 as Depomed, Inc. and renamed Assertio Therapeutics, Inc. in 2018 before becoming Assertio Holdings, Inc., the company is headquartered at 100 South Saunders Road, Suite 300, Lake Forest, Illinois, and primarily operates in the United States. In recent developments, Assertio completed its acquisition of Spectrum Pharmaceuticals, Inc. in 2023 through an all-stock transaction valued at approximately $250 million including contingent value rights, integrating ROLVEDON into its portfolio to enhance oncology capabilities, diversify revenue streams, and leverage complementary commercial infrastructures for accelerated profitability; the company also reported third quarter 2025 financial results and announced a leadership transition, alongside presenting real-world data on Sympazan patient experience.
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
Shareholder Alert: Ademi LLP investigates whether Assertio Holdings Inc. is obtaining a Fair Price for Public Shareholders
Are SILA, UNF, ASRT, KW Obtaining Fair Deals for their Shareholders?
Are SILA, UNF, ASRT, KW Obtaining Fair Deals for their Shareholders?
Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT
Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT
Shareholder Alert: Ademi LLP investigates whether Assertio Holdings Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Assertio Holdings Inc. is obtaining a Fair Price for Public Shareholders
Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash
Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash
Assertio and Garda Mutually Agree to Delay Launch of Tender Offer
Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Assertio and Garda Mutually Agree to Extend Tender Offer Deadline
Assertio Provides Update on Garda Therapeutics Tender Process
Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT
ASRT Stock Alert: Halper Sadeh LLC is Investigating Whether Assertio Holdings, Inc. is Obtaining a Fair Price for its Shareholders